[1]
|
R.G. Urdinguio, J.V. Sanchez-Mut, M. Esteller, “Epigenetic mechanisms in neurological diseases: genes, sindrome, and terapie”, Lancet Neurol, vol. 8, 2009, pp.1056-1072.
|
[2]
|
A.D. Sadovnick, P.A. Baird, R.H. Ward, “Multiple sclerosis: updated risk for relatives”, Am J Med Genet, vol. 29, 1988, pp. 533- 541.
|
[3]
|
O. Olerup, J. Hillert, “HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation”, Tissue Antigens, vol. 38, 1991, pp. 1-15.
|
[4]
|
J.R. Oksenberg, L.F. Barcellos, B.A. Cree, S.E. Baranzini, T.L Bugawan., O. Khan, R.R. Lincoln, A. Swerdlin, E. Mignot, L. Lin, D. Goodin, H.A. Erlich, S. Schmidt, G. Thomson, D.E. Reich, M.A. Pericak-Vance, J.L. Haines, S.L. Hauser, “Mapping Multiple Sclerosis susceptibility to the HLA-DR Locus in African Americans”, Am J Hum Genet, vol. 74, 2004, pp. 160-167.
|
[5]
|
C.F Brosnan, L. Battistini, Y.L Gao, C.S. Raine, D.A. Aquino, “Heat shock proteins and multiple sclerosis: a review”, J Neuropathol Exp Neurol, vol. 55, 1996, pp.389-402.
|
[6]
|
C.G. Proud, “Regulation of eukaryotic initiation factor eIFB”, Prog Mol Subcell Biol, vol. 26, 2001, pp. 95-114.
|
[7]
|
P.A. Leegwater, G. Vermeulen, A.A. K?nst, S. Naidu, J. Mulders, A. Visser, P. Kersbergen, D. Mobach, D. Fonds, C.G. van Berkel, R.J. Lemmers, R.R. Frants, C.B. Oudejans, R.B. Schutgens, J.C. Pronk, M.S. van der Knaap, “Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter”. Nat Genet, vol. 29, 2001, pp. 383-388.
|
[8]
|
A. Fogli, R. Schiffmann, E. Bertini, S. Ughetto, P. Combes, E. Eymard-Pierre, C.R. Kaneski, M. Pineda, M. Troncoso, G. Uziel, R. Surtees, D. Pugin, M.P. Chaunu, D. Rodriguez, O. Boespflug-Tanguy, “The effect of genotype on the natural history of rIF2B-related leukodistrophies”, Neurology, vol. 62, 2004, pp. 1509-1517.
|
[9]
|
M.S. van der Knaap, W. Kamphorst, P.G. Barth, C.L. Kraaijeveld, E. Gut, J. Valk, “Phenotypic variation in leukoencephalopathy with vanishing white matter”, Neurology, vol. 51, 1998, pp. 540-547.
|
[10]
|
Noetzel, M.J. 2004. Diagnosing “undiagnosed” leukodistrophies. The role of molecular genetics. Neurology 62, 847-848.
|
[11]
|
C.M. Poser, D.W. Paty, L. Scheinberg, W.I. McDonald, F.A. Davis, G.C. Ebers, K.P. Johnson, W.A. Sibley, D.H. Silberberg, W.W. Tourtellotte, “New diagnostic criteria for multiple sclerosis: guidelines for research protocols”, Ann Neurol, vol. 13, 1983, pp. 227-231.
|
[12]
|
M.S. van der Knaap, P.A. Leegwater, C.G. van Berkel, C. Brenner, E. Storey, M. Di Rocco, F. Salvi, J.C. Pronk, “Arg113His mutation in eIF2Bepsilon as cause of leukoencephalopathy in adults”, Neurology, vol. 62, 2004, pp.1464-1465.
|
[13]
|
J. Pronk, G. Scheper, R. van Andel, C. van Berkel, Ch. Polman, B. Uitdehaag, M. van der Knaap, “No evidence that polymorphisms of the vanishing white matter disease genes are risk factors in multiple sclerosis”, Mult Scler, vol. 14, 2008, pp. 1123-1126.
|